Literature DB >> 11180901

A multidisciplinary approach to the treatment of malignant pelvic bone tumors: results with eight consecutive patients.

R Yokoyama1, Y Beppu, K Tobisu Ki, Y Moriya, K Uchiyama, M Kito, T Umeda, T Hasegawa, T Shimoda.   

Abstract

The prognosis for malignant pelvic bone tumors is worse than that for malignant bone tumors of the extremities because definitive surgery in the pelvis is often difficult to accomplish. The results for eight patients who were treated consecutively with a multidisciplinary approach, from 1990, were analyzed. The histologic diagnosis was osteosarcoma in five patients, chondrosarcoma in two, and Ewing's sarcoma in one. Five lesions arose in the ilium and three in the pubis. The extraosseous tumors decreased in size and/or were encapsulated as a result of preoperative chemotherapy in six patients, four of these achieving a wide surgical margin. With respect to tumor location and surgical margin, all five lesions in the ilium involved the sacrum, four of these being resected with an inadequate margin. The three lesions in the pubis were resected with an adequate margin. Local recurrence was observed in two patients who had been treated with an inappropriate margin. During the period between 18 and 57 months after the first operation, five patients were continuously free of disease and one was still alive but had lung metastases. Our results indicate that a patient's chances of definitive surgery may be enhanced by a multidisciplinary approach, although the management of sacroiliac involvement remains challenging.

Entities:  

Mesh:

Year:  2000        PMID: 11180901     DOI: 10.1007/s007760070022

Source DB:  PubMed          Journal:  J Orthop Sci        ISSN: 0949-2658            Impact factor:   1.601


  1 in total

1.  Pre-operative embolization facilitating a posterior approach for the surgical resection of giant sacral neurogenic tumors.

Authors:  Kangwu Chen; Ming Zhou; Huilin Yang; Zhonglai Qian; Genlin Wang; Guizhong Wu; Xiaoyu Zhu; Zhiyong Sun
Journal:  Oncol Lett       Date:  2013-05-08       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.